Let this be a lesson in the volatile biotech market --> CAPTIAL PRESERVATION IS KEY.
ARNA climbed to $5.72 today on pure speculation of VVUS's drug candidate Qnexa not getting a thumbs up from the FDA. BUT... The FDA gave VVUS a THUMBS DOWN (at least that's the rumor)... now look what happens to ARNA. CRASH...
Good thing I took some profits today, but I still hold shares and will buy back in after the overreaction ends! Investors might have less faith in the metabolic drug category....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.